Study Title

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent

Study Details

Description:

This study aims to establish the recommended dose of [177Lu]Lu-DOTA-TATE in combination with the standard of care or as single agent in three different groups of participants with Glioblastoma (a brain cancer).

Sponsor:

Novartis

Government Study Link:

NCT05109728 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

University of Wisconsin